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Summary
In the post-genomic era of medicine, histopathological assessment of colorectal carcinoma 
specimens plays the key role in the comprehensive management of patients with colorectal can-
cer. Adequate specimen handling and dissection is a crucial step in obtaining a precise and accu-
rate pathohistologic report. Microscopic analysis must give information on:  histological tumour 
type and differentiation, maximum extent of local invasion (pT stage), grade of tumour regression 
following pre-operative (neoadjuvant) therapy, resection margins (longitudinal and circumferen-
tial margins), lymph node status, venous invasion, MSI status and other abnormal findings. Latest 
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer 
emphasize the pathologist’ role in this process. Recently defined molecular subtypes of colorec-
tal cancer will hopefully serve as the basis for future trials.
Keywords: colorectal carcinoma; histopathology report; adequate specimen handling; prog-
nostic factors; predictive factors; molecular pathology.
INTRODUCTION
In the post-genomic era of medicine, histopathological assessment of colorectal 
carcinoma specimens plays the key role in the comprehensive management of pa-
tients with colorectal cancer. A pathological report must contain some crucial data 
that are essential to plan the treatment and follow-up of individual patients. Cu-
rrently valid Croatian National Guidelines for the examination and reporting of 
colorectal resection specimens containing carcinoma were presented at the fifth 
Congress of Croatian Society of Pathology and Forensic Medicine in 2012 (Zagreb) 
and adopted in 2016 at the sixth Congress of Croatian Society of Pathology and 
Forensic Medicine (Osijek) [1]. These guidelines are very thoroughly explained in 
a recently published paper by Jakić-Razumović [2]. This review will address some 
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of the most important ones and introduce up-to-date ESMO consensus guidelines 
for the management of patients with metastatic colorectal cancer that are related to 
pathohistologic report [3].
SPECIMEN  HANDLING
Adequate specimen handling and dissection is a crucial step in obtaining a pre-
cise and accurate pathohistologic report. According to the Royal College of Patho-
logists colorectal cancer dataset it would be ideal to receive specimens fresh and 
unopened as soon as possible after surgical resection. Since such a practice is hard 
to achieve in routine daily work it is than necessary to deliver specimens in a large 
volume of formaline fixative [4]. But, before a pathologist even starts to macrosco-
pically examine and cut the specimen, he/she must be informed on the patients’ 
medical history such as adjuvant chemo/radiotherapy, prior operations, history of 
inflammatory bowel disease etc.  Surgical specimen is then inspected to locate the 
tumour and the presence of perforation if present [2,5,6]. After assessing proximal 
and distal surgical margins, the circumferential (non-peritonealised) surgical resec-
tion margin should also be assessed. If the tumor is in the vicinity of it, the circum-
ferential margin should be inked to enable the precise microscopic identification of 
its involvement [2,5,6]. As a minimum, four blocks of tumor tissue should be taken 
to assess: the deepest level of tumor penetration, involvement of serosal surface, in-
vasion of veins and involvement of any adjacent organ if present [4].  If tumor is near 
the circumferential resection margin, a block of tissue to show the closest approxi-
mation should also be sampled [2,4]. Serosal involvement is best identified if blocks 
are taken from areas that are dulled or fibrotic. At least two blocks taken from these 
areas are recommended [7].  Venous invasion can be suspected macroscopically as 
fine pale lines radiating from the base of the tumour [4]. All lymph nodes identified 
must be sampled. Factors influencing total lymph node harvest are numerous and 
can be divided in two major groups: modifiable and non-modifiable [8]. Non-mo-
difiable factors include patients’ gender, ethnicity, age, socioeconomic class, body 
mass index, tumour location, size, histological subtype, stage, microsatellite instabi-
lity, lymph node positivity/negativity, lymphovascular invasion. Modifiable factors 
include tumour inking, neoadjuvant therapy, surgical technique and pathologists’ 
engagement and knowledge while dissecting specimen [8]. The most usual and im-
portant modifiable factor influencing lymph node yield, especially in rectal cancer, 
is the preoperative chemo/radiotherapy and this procedure must be clearly stated 
[9]. The median number of lymph nodes examined should be greater than 12 [2,4]. 
Data regarding recommendations as to whether lymph nodes are embedded entire-
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ly are still insufficient. There are some recommendations to embed small nodes (<4 
mm) entirely and to take a single block through the longest axis of larger nodes [4]. 
Additionally, every other abnormal finding related to the surrounding mucosa or 
other structures should also be sampled.
PATHOLOGICAL  REPORT  AND  PERSONALIZED  MEDICINE 
Once a pathologist has properly examined and cut all relevant tissue blocks, 
material is routinely processed and standard hematoxylin-eosin slides are provided 
and analyzed under the light microscope. Results of the microscopic analysis are, in 
the vast majority of cases, the very basis for the upcoming decisions regarding pa-
tients’ management and follow-up. Microscopic analysis must give information on: 
histological tumour type and differentiation, maximum extent of local invasion (pT 
stage), grade of tumour regression following pre-operative (neoadjuvant) therapy, 
resection margins (longitudinal and circumferential margins), lymph node status, 
venous invasion, MSI status and other abnormal findings [2,4]. For the microscopic 
assessment of tumour type the WHO classification from 2010 is recommended [10]. 
Morphological assessment of differentiation applies only to ‘Adenocarcinoma, NOS’ 
and not to specific variants [10]. The maximum degree of local invasion into or thro-
ugh the bowel wall is the criterion for pT staging [11]. All of the above mentioned 
parameters are nicely described in the Croatian National Guidelines and explained 
in the paper by Jakić-Razumović [2]. Mismatch repair (MMR) status can be evalua-
ted by immunohistochemistry, applying a panel of four antibodies (MLH1, PMS2, 
MSH2, MSH6). Tumours that are microsatellite instability-high (MSI-H) usually de-
monstrate mucinous or medullary differentiation [12].  
Latest ESMO consensus guidelines for the management of patients with meta-
static colorectal cancer emphasize the pathologist’ role in this process [3]. Several 
recommendations regarding biomarker testing (RAS, BRAF, MSI) are published and 
will be concisely presented. It is stated that standardization of tissue processing 
of specimens obtained from patients with metastatic colorectal cancer is hard to 
achieve [3]. The time from tissue sampling to fixation should be minimized to a few 
minutes to prevent degradation of proteins and nucleic acids [13,14]. Fixation with 
10% neutral buffered formalin is recommended and fixation time should not be less 
than 6 hours and no greater than 48 hours [3]. The primary pathologist should re-
view specimens and select ones that are suitable for biomarker testing and has to 
ensure that a selected specimen contains sufficient quantity of neoplastic cells [3,15]. 
It is recommended that a sample should contain at least 50% of tumour versus non-
tumor cells [3]. Regarding RAS mutation testing, tissue from the primary tumour 
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or a liver metastasis can be used for this purpose. Lymph node metastases are not 
suitable for RAS mutation testing. But, lung or lymph node metastases can both be 
used if tissue from primary tumour or liver metastasis is not available [3]. BRAF mu-
tation testing is supposed to be assessed alongside with RAS mutation testing as it 
has strong prognostic value and can be potentially important for clinical trials [3]. It 
is stated that MSI testing can be helpful in genetic counseling. Moreover MSI status 
has strong predictive value for the effectiveness of immune check-point inhibitors 
when concerning treatment options [3]. 
Colorectal cancer is a heterogenous disease and none of the existing gene expre-
ssion profiles have managed to accurately predict recurrence or prognosis for pa-
tients with this disease [3]. Recently, an international molecular classification has 
been adopted [16].  There are four molecular subtypes of colorectal cancer CMS1 
(MSI Immune) – hypermutated, microsatellite unstable with strong immune acti-
vation; CMS2 (Canonical) – epithelial, chromosomally unstable, with marked WNT 
and MYC signaling activation; CMS3 (Metabolic) – epithelial, with metabolic dysre-
gulation; CMS4 (Mesenchymal) – prominent TGFβ activation, stromal invasion and 
angiogenesis. Hopefully, this will serve as the basis for future trials.
CONCLUSION
Accurate pathology reporting of colorectal cancer resection specimen is crucial 
because it gives essential information that help plan the treatment of individual 
patients. Moreover, it contains some key prognostic parameters. Appropriate speci-
men handling in the operation room as well as precise macroscopic and microscopic 
examination performed by pathologist are vital for obtaining reliable pathohisto-
logic report. These are also prerequisites for accurate molecular analysis.  In order 
to achieve and maintain high-quality clinical management, it is advised to make 
decisions for individual patients in a multidisciplinary team.  
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Sažetak
Preporuke za patohistološki pregled i nalaz uzoraka debelog crijeva s karcinomom
U post-genomskoj eri medicine, patohistološka procjena uzoraka karcinoma debelog crijeva 
i dalje igra ključnu ulogu u cjelovitom i kvalitetnom pristupu pacijentima oboljelima od ove bo-
lesti. Odgovarajuće postupanje sa samim uzorkom temelj je za dobivaje cjelovitog i svrsishodnog 
patohistološkog nalaza. Mikroskopska analiza mora dati podatke o: histološkom tipu tumora i 
gradusu, lokalnoj proširenosti (pT stadij), gradusu regresije tumora nakon neoadjuvantne terapije, 
resekcijskim rubovima (proksimalnom, distalnom i radijalnom), statusu limfnih čvorova, vaskular-
noj invaziji, MSI statusu i ostalim patološkim nalazima ako postoje. U najnovijim ESMO smjerni-
cama, a koje se odnose na upute o postupanju s pacijentima koji imaju metastatski kolorektalni 
karcinom, naglašena je važna uloga patologa u ovome procesu. Nedavno definirani molekularni 
podtipovi kolorektalnog karcinoma pružaju bazu za buduća istraživanja.
Ključne riječi: kolorektalni karcinom; patohistološki nalaz; odgovarajuće postupanje uzor-
kom; prognostički čimbenici; prediktivni čimbenici; molekularna patologija.
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